Basic Stats
| CIK | 1801777 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Applied Molecular Transport Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| February 14, 2024 |
SC 13G/A 1 tm245429d47sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Molecular Transport Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this S |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39306 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as spe |
|
| January 5, 2024 |
EX-2 3 ex99.2.htm EXHIBIT 99.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other |
|
| January 5, 2024 |
EX-1 2 99.1.htm EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock of the Issuer and further agree that this joint filing agreement be include |
|
| January 5, 2024 |
AMTI / Applied Molecular Transport Inc. / EPIQ Capital Group, LLC - EPIQ13D1 Activist Investment SC 13D/A 1 epiq13d1.htm EPIQ13D1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Molecular Technologies Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03824M109 (CUSIP Number) Jed Clark General Counsel and CCO, EPIQ Capital Group, 1 Lombard Stree |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -12-31 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorpor |
|
| December 27, 2023 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION APPLIED MOLECULAR TRANSPORT INC. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED MOLECULAR TRANSPORT INC. FIRST: The name of the Corporation is Applied Molecular Transport Inc. (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, City of Wilmington, county of New Castle, Delaware 19808. The name of its regi |
|
| December 27, 2023 |
Exhibit 3.2 APPLIED MOLECULAR TRANSPORT INC. Incorporated under the laws of the State of Delaware AMENDED AND RESTATED BY-LAWS As Adopted on December 27, 2023 AMENDED AND RESTATED BY-LAWS OF APPLIED MOLECULAR TRANSPORT INC. (a Delaware corporation) (adopted December 27, 2023) ARTICLE I OFFICES Section 1.01 Offices. The address of the registered office of Applied Molecular Transport Inc. (the “Corp |
|
| December 26, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 9, 2023 |
Exhibit 99.1 Applied Molecular Transport Reports Third Quarter 2023 Financial Results Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., November 9, 2023 — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| September 21, 2023 |
Exhibit 99.1 Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milest |
|
| September 21, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Among Cyclo Therapeutics, Inc. Cameo Merger Sub, Inc. And Applied Molecular Transport Inc. Dated as of September 21, 2023 Table of Contents Page ARTICLE I The Merger 1 Section 1.01 The Merger 1 Section 1.02 Closing 1 Section 1.03 Effective Time 2 Section 1.04 Effects 2 Section 1.05 Certificate of Incorporation and Bylaws 2 Section 1.06 Directors 2 Section 1 |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| September 21, 2023 |
Exhibit 10.1 VOTING AGREEMENT This Voting Agreement (this “Voting Agreement”) is being delivered on September [•], 2023 by the person or persons named on the signature pages hereto (collectively, the “Holder”), as the holder of Company Shares (as defined below) of Applied Molecular Transport Inc., a Delaware corporation (the “Company”), to Cyclo Therapeutics, Inc., a Nevada corporation (“Parent”). |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 14, 2023 |
Exhibit 99.1 Applied Molecular Transport Reports Second Quarter 2023 Financial Results Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., August 14, 2023 — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financia |
|
| August 14, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (C |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (C |
|
| July 24, 2023 |
EX-10.1 Exhibit 10.1 APPLIED MOLECULAR TRANSPORT, INC. SENIOR EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY (Effective as of June 1, 2023) This Senior Executive Change in Control and Severance Policy (the “Policy”) is designed to provide certain protections to a select group of designated key employees of Applied Molecular Transport, Inc. (“AMT” or the “Company”) or any of its subsidiaries if t |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Com |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 (June 14, 2023) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of inc |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Comm |
|
| June 8, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 11, 2023 |
Exhibit 10.5 AGREEMENT FOR MODIFICATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Modification of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of May 2, 2023, by and between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”), with refe |
|
| May 11, 2023 |
Applied Molecular Transport Reports First Quarter 2023 Financial Results Exhibit 99.1 Applied Molecular Transport Reports First Quarter 2023 Financial Results SOUTH SAN FRANCISCO, Calif., May 11, 2023 — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights •Engaged MTS Health Partners, L.P. as advisors in a process to explore strategic a |
|
| May 11, 2023 |
Exhibit 10.4 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of May 2, 2023, but effective as of 11:59 PM Pacific Time on March 31, 2023, by and between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that c |
|
| May 11, 2023 |
Exhibit 10.3 APPLIED MOLECULAR TRANSPORT INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of April 10, 2023 (the “Effective Date”) by and between Applied Molecular Transport Inc., a Delaware corporation having its principal place of business located at 450 East Jamie Court, South San Francisco, CA 94080 (the “Company”), and Lake Sherwood Partners, |
|
| May 11, 2023 |
Separation Agreement, dated March 8, 2023, by and between Bittoo Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Bittoo Kanwar (“Employee”) and Applied Molecular Transport Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an At-Will Employment, Confident |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Comm |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 11, 2023 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Tahir Mahmood (“Employee”) and Applied Molecular Transport Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an At-Will Employment, Confident |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 (May 2, 2023) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorpo |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 27, 2023 |
Exhibit 99.1 Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives SOUTH SAN FRANCISCO, Calif., March 27, 2023 — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 (March 21, 2023) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of i |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 (March 7, 2023) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of inc |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number -001-39 |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Com |
|
| March 9, 2023 |
Exhibit 99.1 Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 9, 2023 — Applied Molecular Tr |
|
| February 9, 2023 |
AMTI / Applied Molecular Transport Inc. / Mahmood Tahir Ph.D. - SC 13G/A Passive Investment SC 13G/A 1 d395736dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Molecular Transport, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 (February 8, 2023) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction |
|
| February 3, 2023 |
AMTI / Applied Molecular Transport Inc. / Mrsny Randall Ph.D. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Molecular Transport, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 (December 29, 2022) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction |
|
| December 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39306 82-4481426 (State or Other Jurisdiction of Incorporation) |
|
| December 22, 2022 |
Exhibit 99.1 Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis - Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 - AMT-101 was well-tolerated - Planned Phase 1b trial for the company?s second clinical asset, AMT-126, i |
|
| November 7, 2022 |
Exhibit 99.1 Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update Company held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products Anticipate Phase 2 top-line readout for oral AMT-101 in UC monotherapy in late 2022 or early 2023, consistent |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) July 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| August 4, 2022 |
Exhibit 99.1 Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis ? Orphan indication with no FDA-approved products ? Company granted end of Phase 2 meeting with FDA to discuss advancing into Phase 3 development Announced top-line data for AMT-101 MARKET Phase |
|
| August 4, 2022 |
Separation Agreement by and between the Company and Randall Mrsny, dated June 15 2022.*# Certain information in this exhibit has been omitted because it is both not material and is the type of information that the registrant treats as private and confidential. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Aug 4, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Commi |
|
| July 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39306 82-4481426 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 6, 2022 |
Exhibit 99.1 Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis - Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 - Post hoc analysis of patie |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 (May 24, 2022) APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 82-4481426 (State or other jurisdiction of incor |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 (May 13, 2022) APPLIED MOLECULAR TRANSPORT INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39306 82-4481426 (State or Other Jurisdiction of Incor |
|
| May 18, 2022 |
Exhibit 99.1 Applied Molecular Transport Provides Strategy Update Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance Company implements co |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 9, 2022 |
Exhibit 99.1 Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis ? Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Commi |
|
| April 25, 2022 |
Exhibit 99.1 Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis - Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD) - AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class pro |
|
| April 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39306 82-4481426 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 12, 2022 |
DEF 14A 1 ny20002282x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Co |
|
| April 6, 2022 |
. Applied Molecular Transport Appoints Charlene Banard to its Board of Directors Exhibit 99.1 . Applied Molecular Transport Appoints Charlene Banard to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 6, 2022 ? Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30 years of expe |
|
| March 29, 2022 |
Up to $150,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263501 PROSPECTUS SUPPLEMENT Up to $150,000,000 Common Stock We previously entered into a Sales Agreement (the ?Sales Agreement?) with SVB Securities LLC, previously known as SVB Leerink LLC (?SVB?), and JMP Securities LLC (?JMP Securities?) (each an ?Agent? and collectively the ?Agents?), dated January 27, 2022, relating to t |
|
| March 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| March 25, 2022 |
CORRESP 1 filename1.htm Applied Molecular Transport Inc. 450 East Jamie Court South San Francisco, California 94080 March 25, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Applied Molecular Transport Inc. Registration Statement on Form S-3 Filed March 11, 2022 File No. 333-263501 Acceleration Request Requested Date: |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. |
|
| March 11, 2022 |
Exhibit 4.4 APPLIED MOLECULAR TRANSPORT INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establis |
|
| March 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 APPLIED MOLECULAR TRANSPORT INC. |
|
| March 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Applied Molecular Transport Inc. |
|
| March 4, 2022 |
As filed with the Securities and Exchange Commission on March 4, 2022 As filed with the Securities and Exchange Commission on March 4, 2022 Registration No. |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39306 82-4481426 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 4, 2022 |
Exhibit 10.1 APPLIED MOLECULAR TRANSPORT INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number -001-39306 APPLIED MOLECU |
|
| February 24, 2022 |
Exhibit 4.3 DESCRIPTION OF capital stock The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our amended and restated certificate of incorporation and the amended and restated bylaws, copies of which are filed with the Securities and Exchange C |
|
| February 24, 2022 |
2020 Equity Incentive Plan and forms of agreement thereunder. Exhibit 10.4 APPLIED MOLECULAR TRANSPORT INC. 2020 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Sto |
|
| February 24, 2022 |
Exhibit 99.1 Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as follows ? FILLMORE monotherapy trial for patients with chronic pouchitis followed by MARKET combination trial with anti-TNF? in ulcerative colitis (UC) in H1 2022 ? LOMBARD monoth |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 applied molecular traNsport inc. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| February 11, 2022 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| February 11, 2022 |
AMTI / Applied Molecular Transport Inc. / Mrsny Randall Ph.D. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Molecular Transport, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 11, 2022 |
AMTI / Applied Molecular Transport Inc. / Mahmood Tahir Ph.D. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Molecular Transport, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| January 28, 2022 |
Exhibit 1.1 APPLIED MOLECULAR TRANSPORT INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT January 27, 2022 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 JMP SECURITIES LLC 600 Montgomery Street, Suite 1100 San Francisco, California 94111 Ladies and Gentlemen: Applied Molecular Transport Inc., a Delaware corporation (the ?Company?), confirm |
|
| January 28, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-257592 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common stock, par value $0. |
|
| January 27, 2022 |
Executive Chair Letter Agreement between the Company and Graham Cooper, dated January 27, 2022. Exhibit 10.1 450 East Jamie Court South San Francisco, CA 94080 January 25, 2022 Graham Cooper RE: Appointment as Executive Chairman of Applied Molecular Transport Inc. Dear Graham, This Letter of Agreement (this ?Agreement?) confirms your appointment as Executive Chairman of Applied Molecular Transport Inc. (the ?Company?) and your continued service as a member of the Company?s Board of Directors |
|
| January 27, 2022 |
Exhibit 99.1 Applied Molecular Transport Announces Board Appointments John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair Graham K. Cooper Named Executive Chair Helen S. Kim Named Lead Independent Director SOUTH SAN FRANCISCO, Calif., January 27, 2022 ? Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| November 10, 2021 |
Exhibit 99.1 Applied Molecular Transport Reports Third Quarter 2021 Financial Results and Provides Corporate Update Top-line data readout for oral AMT-101 Phase 2 MARKET combination trial with anti-TNF? in ulcerative colitis (UC) expected in H1 2022 Top-line data readouts from three additional oral AMT-101 Phase 2 trials, consistent with previous guidance ? FILLMORE monotherapy trial in pouchitis |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| August 25, 2021 |
Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors Exhibit 99.1 Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors SOUTH SAN FRANCISCO, Calif., August 24, 2021 ? Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished industry veteran to its Board of Directors. ?We are very excited to wel |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (C |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 10, 2021 |
Exhibit 99.1 Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance ? Combination trial of AMT-101 with anti-TNF? in moderate-to-severe ulcerative colitis (UC) patients in the fourth quarter of 2021; ? Monotherapy trial in pouchitis, combinati |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 applied molecular traNsport inc. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (C |
|
| July 1, 2021 |
As filed with the Securities and Exchange Commission on July 1, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 1, 2021 Registration No. |
|
| May 19, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Comm |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 applied molecular traNsport inc. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Comm |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 13, 2021 |
Exhibit 99.1 Applied Molecular Transport Reports First Quarter 2021 Financial Results and Provides Corporate Update Enrollment ongoing in each of oral AMT-101?s four Phase 2 trials On track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials, being conducted in multiple ulcerative colitis populations and rheumatoid arthritis, beginning in the second half of 2021 and into 2 |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) April 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) April 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| April 7, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def |
|
| April 1, 2021 |
424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-254822 P R O S P E C T U S 2,500,000 Shares Common Stock We are offering 2,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “AMTI.” On March 31, 2021, the last reported sale price of our common stock on the Nasdaq Global Select Market was $44.01 per share. |
|
| March 29, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 APPLIED MOLECULAR TRANSPORT INC. (a Delaware corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [?], 2021 APPLIED MOLECULAR TRANSPORT INC. (a Delaware corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT [?], 2021 BofA Securities, Inc. Jefferies LLC SVB Leerink LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New |
|
| March 29, 2021 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 o: 650. |
|
| March 29, 2021 |
March 29, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 29, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 19, 2021 |
As filed with the Securities and Exchange Commission on March 19, 2021 Registration No. |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number -001-39306 APPLIED MOLECU |
|
| March 19, 2021 |
Offer Letter dated November 24, 2020 by and between the Registrant and Douglas Rich. Exhibit 10.15 November 24, 2020 Mr. Douglas Rich Dear Doug: I am pleased to offer you the position of Chief Technology Operations Officer at Applied Molecular Transport Inc. (the ?Company?) in South San Francisco, CA reporting to me. If you decide to join us, you will receive an annual salary of three hundred and eighty thousand US dollars ($380,000). The salary will be paid semimonthly in accorda |
|
| March 19, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 applied molecular traNsport inc. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (Co |
|
| March 19, 2021 |
2020 Equity Incentive Plan and forms of agreement thereunder. Exhibit 10.4 APPLIED MOLECULAR TRANSPORT INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive St |
|
| March 19, 2021 |
2020 Employee Stock Purchase Plan Exhibit 10.5 APPLIED MOLECULAR TRANSPORT INC. 2020 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective November 22, 2020) 1.Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intend |
|
| March 19, 2021 |
Table of Contents Confidential Treatment Requested by Applied Molecular Transport Inc. |
|
| March 19, 2021 |
Exhibit 99.1 Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program, in multiple ulcerative colitis populations |
|
| March 19, 2021 |
Exhibit 4.3 DESCRIPTION OF capital stock The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our amended and restated certificate of incorporation and the amended and restated bylaws, copies of which are filed with the Securities and Exchange C |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. ) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Applied Molecular Transport Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to desig |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Molecular Transport Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 12, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Molecular Transport, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 12, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Molecular Transport, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03824M109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 10, 2021 |
EX-10.1 Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 5th day of February, 2021, between ARE-EAST JAMIE COURT, LLC, a Delaware limited liability company (“Landlord”), and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation (“Tenant”). Building: 450 East Jamie Court, South San Francisco, California Premises: The entire Building, containing approximately 84,321 r |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2021 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 applied molecular traNsport inc. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) |
|
| November 12, 2020 |
Exhibit 99.1 Applied Molecular Transport Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Company on track with comprehensive AMT-101 Phase 2 clinical program across multiple indications, including inflammatory bowel diseases and rheumatoid arthritis - - Announced dosing of first patient in Phase 2 monotherapy trial (LOMBARD) evaluating the efficacy and safety of oral A |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 applied molecular traNsport inc. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 11, 2020 |
Applied Molecular Transport Reports Second Quarter 2020 Financial Results Exhibit 99.1 Applied Molecular Transport Reports Second Quarter 2020 Financial Results - Company debuts with successful $177 million IPO - Plans to initiate three Phase 2 clinical trials for AMT-101 in 2020; anticipates top-line data readouts in 2H 2021 and 1H 2022 - On track to file IND/CTA by year-end 2020 for AMT-126, AMT’s second therapeutic product candidate SOUTH SAN FRANCISCO, August 11, 20 |
|
| June 18, 2020 |
Lock-Up Agreement February 10, 2020 Lock-Up Agreement February 10, 2020 BofA Securities, Inc. Jefferies LLC SVB Leerink LLC as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 0211 |
|
| June 18, 2020 |
Lock-Up Agreement February 10, 2020 Lock-Up Agreement February 10, 2020 BofA Securities, Inc. Jefferies LLC SVB Leerink LLC as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 0211 |
|
| June 18, 2020 |
AMTI / Applied Molecular Transport Inc. / EPIQ Capital Group, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No.)1 Applied Molecular Technologies Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03824M109 (CUSIP Number) Je |
|
| June 18, 2020 |
Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. |
|
| June 9, 2020 |
Amended and Restated Bylaws of the Registrant. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF APPLIED MOLECULAR TRANSPORT INC. (as amended on May 29, 2020 and effective as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page ARTICLE I—CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II—MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVAN |
|
| June 9, 2020 |
Amended and Restated Certificate of Incorporation of the Registrant. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED MOLECULAR TRANSPORT INC. Applied Molecular Transport Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A. The name of the Corporation is Applied Molecular Transport Inc. The Corporation was originally incorporated pursuant to the Gene |
|
| June 9, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 001-39306 81-4481426 (State or other jurisdiction of incorporation) ( |
|
| June 9, 2020 |
EX-99.1 Exhibit 99.1 Applied Molecular Transport Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., June 9, 2020 — Applied Molecular Transport (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today announced the closing of its initial public offering of 12,650,000 shares of its common s |
|
| June 5, 2020 |
June 5, 2020 (Registration No. 333-238981) S-8 As filed with the Securities and Exchange Commission on June 5, 2020 Registration No. |
|
| June 5, 2020 |
11,000,000 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-238464 P R O S P E C T U S 11,000,000 Shares Common Stock This is an initial public offering of shares of common stock of Applied Molecular Transport Inc. We are selling 11,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price i |
|
| June 4, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on June 4, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied Molecular Transport Inc (Exact name of registrant as specified in its charter) Delaware 2834 81-4481426 (State or other jurisdiction of incorporation or org |
|
| June 2, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 81-4481426 (State of incorporation or organization) (I.R.S. Employer Identification No.) 1 To |
|
| June 2, 2020 |
Company Acceleration Request June 2, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 2, 2020 |
Underwriters' Acceleration Request June 2, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 1, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 APPLIED MOLECULAR TRANSPORT INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [●], 2020 APPLIED MOLECULAR TRANSPORT INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENT [●], 2020 BofA Securities, Inc. Jefferies LLC SVB Leerink LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Pa |
|
| June 1, 2020 |
Amendment No. 1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 1, 2020. Registration No. 333-238464 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 APPLIED MOLECULAR TRANSPORT INC. (Exact name of registrant as specified in its charter) Delaware 283 |
|
| June 1, 2020 |
EX-10.9 Exhibit 10.9 1 Tower Place, Suite 850 South San Francisco, CA 94080 Phone: (650) 392-0420 June 1, 2020 Bittoo Kanwar, MD Via email Dear Bittoo: This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering of |
|
| June 1, 2020 |
2020 Equity Incentive Plan and forms of agreement thereunder. EX-10.4 Exhibit 10.4 APPLIED MOLECULAR TRANSPORT INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Ince |
|
| June 1, 2020 |
EX-10.10 Exhibit 10.10 1 Tower Place, Suite 850 South San Francisco, CA 94080 Phone: (650) 392-0420 June 1, 2020 Elizabeth Bhatt Via email Dear Elizabeth: This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering |
|
| June 1, 2020 |
Outside Director Compensation Policy. EX-10.7 Exhibit 10.7 APPLIED MOLECULAR TRANSPORT INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved by the Board of Directors on May 29, 2020 Applied Molecular Transport Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retai |
|
| June 1, 2020 |
2020 Employee Stock Purchase Plan. EX-10.5 Exhibit 10.5 APPLIED MOLECULAR TRANSPORT INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an employee stock purchase |
|
| June 1, 2020 |
Senior Executive Change in Control and Severance Policy. EX-10.15 Exhibit 10.15 APPLIED MOLECULAR TRANSPORT, INC. SENIOR EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY (Adopted on June 1, 2020) This Senior Executive Change in Control and Severance Policy (the “Policy”) is designed to provide certain protections to a select group of designated key employees of Applied Molecular Transport, Inc. (“AMT” or the “Company”) or any of its subsidiaries if thei |
|
| June 1, 2020 |
EX-10.13 Exhibit 10.13 1 Tower Place, Suite 850 South San Francisco, CA 94080 Phone: (650) 392-0420 June 1, 2020 Brandon Hants Via email Dear Brandon: This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering of |
|
| June 1, 2020 |
EX-10.8 Exhibit 10.8 1 Tower Place, Suite 850 South San Francisco, CA 94080 Phone: (650) 392-0420 June 1, 2020 Tahir Mahmood Via email Dear Tahir: This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering of the |
|
| June 1, 2020 |
EX-10.11 Exhibit 10.11 1 Tower Place, Suite 850 South San Francisco, CA 94080 Phone: (650) 392-0420 June 1, 2020 Randall Mrsny Via email Dear Randall: This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering of |
|
| June 1, 2020 |
Executive Incentive Compensation Plan. EX-10.6 Exhibit 10.6 APPLIED MOLECULAR TRANSPORT INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (i) perform to the best of their abilities and (ii) achieve the Company’s objectives. 2. Definitions. (a) “Actual Award” means as to any Performance Period, the actual award |
|
| June 1, 2020 |
EX-10.12 Exhibit 10.12 1 Tower Place, Suite 850 South San Francisco, CA 94080 Phone: (650) 392-0420 June 1, 2020 Shawn Cross Via email Dear Shawn: This letter agreement (the “Agreement”) is entered into between you and Applied Molecular Transport Inc. (the “Company” or “we”), effective as of the effective date of the Company’s S-1 registration in connection with the initial public offering of the |
|
| May 20, 2020 |
Correspondence 650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com CONFIDENTIAL TREATMENT REQUESTED BY APPLIED MOLECULAR TRANSPORT INC.: AMTI-001 FOIA Confidential Treatment Requested Pursuant to 17 C.F.R. §200.83 The entity requesting confidential treatment is: Applied Molecular Transport Inc. 1 Tower Place, Suite 850 South San Francisco, CA 94080 Attention: Tahir M |
|
| May 18, 2020 |
Amended and Restated Investors’ Rights Agreement, dated September 30, 2019. EX-4.1 Exhibit 4.1 APPLIED MOLECULAR TRANSPORT INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 30, 2019 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 4 2.1 Requested Registration 4 2.2 Company Registration 6 2.3 Registration on Form S-3 7 2.4 Expenses of Registration 7 2.5 Registration Procedures 7 2.6 Indemnification 9 2.7 I |
|
| May 18, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on May 18, 2020. |
|
| May 18, 2020 |
Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED MOLECULAR TRANSPORT INC. Applied Molecular Transport Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Applied Molecular Transport Inc. The Corporation’s original Certificate of Incorporation was filed with the |
|
| May 18, 2020 |
Bylaws of the Registrant, as currently in effect. EX-3.3 Exhibit 3.3 BYLAWS OF APPLIED MOLECULAR TRANSPORT INC. Adopted November 22, 2016 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting |
|
| May 18, 2020 |
Lease Agreement between AP3-SF2 CT South, LLC, dated December 18, 2016. EX-10.12 Exhibit 10.12 ONE TOWER PLACE LEASE AP3-SF2 CT SOUTH, LLC, a Delaware limited liability company as Landlord, and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation as Tenant SUMMARY OF BASIC LEASE INFORMATION This Summary of Basic Lease Information (Summary) is hereby incorporated into and made a part of the attached Lease. Each reference in the Lease to any term of this Summary s |
|
| May 18, 2020 |
2016 Equity Incentive Plan and forms of agreement thereunder. EX-10.3 Exhibit 10.3 APPLIED MOLECULAR TRANSPORT INC. 2016 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Ince |
|
| May 18, 2020 |
Specimen common stock certificate of the Registrant. EX-4.2 Exhibit 4.2 The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the Cor |
|
| May 18, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED MOLECULAR TRANSPORT INC. Applied Molecular Transport Inc., a corporation organized and existing under the laws of the State of Delaware (the Corporation), does hereby certify as follows: A. The name of the Corporation is Applied Molecular Transport Inc. The Corporation was originally incorporated pursuant to the Gene |
|
| May 18, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF APPLIED MOLECULAR TRANSPORT INC. (initially adopted on November 22, 2016) (as amended on , 2020 and effective as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page ARTICLE I—CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II—MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETIN |
|
| May 18, 2020 |
2015 Equity Incentive Plan and forms of agreement thereunder. EX-10.2 Exhibit 10.2 APPLIED MOLECULAR TRANSPORT, LLC 2015 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this 2015 Equity Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility and to provide additional incentive to Employees, Directors or Consultants to promote the success of the Company’s business. The Plan permits the g |
|
| May 18, 2020 |
EX-10.1 Exhibit 10.1 APPLIED MOLECULAR TRANSPORT INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [ , 2020] and is between Applied Molecular Transport Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluc |
|
| April 10, 2020 |
DRSLTR 650 Page Mill Road Palo Alto, CA 94304-1050 PHONE 650.493.9300 FAX 650.493.6811 www.wsgr.com April 10, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Michael Clampitt Jessica Livingston Vanessa Robertson David Burton Re: Applied Molecular Transport Inc. Draft Registratio |
|
| April 10, 2020 |
Draft Registration Statement No. 2 Table of Contents Amendment No. 1 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on April 10, 2020. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIE |
|
| February 13, 2020 |
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED MOLECULAR TRANSPORT INC. EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED MOLECULAR TRANSPORT INC. Applied Molecular Transport Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Applied Molecular Transport Inc. The Corporation’s original Certificate of Incorporation was filed with the |
|
| February 13, 2020 |
Draft Registration Statement Table of Contents As confidentially submitted to the Securities and Exchange Commission on February 13, 2020. |
|
| February 13, 2020 |
APPLIED MOLECULAR TRANSPORT INC. 2016 EQUITY INCENTIVE PLAN EX-10.3 6 filename6.htm Exhibit 10.3 APPLIED MOLECULAR TRANSPORT INC. 2016 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits t |
|
| February 13, 2020 |
EX-10.13 Exhibit 10.13 ONE TOWER PLACE LEASE AP3-SF2 CT SOUTH, LLC, a Delaware limited liability company as Landlord, and APPLIED MOLECULAR TRANSPORT INC., a Delaware corporation as Tenant SUMMARY OF BASIC LEASE INFORMATION This Summary of Basic Lease Information (“Summary”) is hereby incorporated into and made a part of the attached Lease. Each reference in the Lease to any term of this Summary s |
|
| February 13, 2020 |
BYLAWS OF APPLIED MOLECULAR TRANSPORT INC. Adopted November 22, 2016 EX-3.3 3 filename3.htm Exhibit 3.3 BYLAWS OF APPLIED MOLECULAR TRANSPORT INC. Adopted November 22, 2016 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Wi |
|
| February 13, 2020 |
APPLIED MOLECULAR TRANSPORT, LLC 2015 EQUITY INCENTIVE PLAN EX-10.2 Exhibit 10.2 APPLIED MOLECULAR TRANSPORT, LLC 2015 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this 2015 Equity Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility and to provide additional incentive to Employees, Directors or Consultants to promote the success of the Company’s business. The Plan permits the g |
|
| February 13, 2020 |
APPLIED MOLECULAR TRANSPORT INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 30, 2019 EX-4.1 Exhibit 4.1 APPLIED MOLECULAR TRANSPORT INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 30, 2019 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 4 2.1 Requested Registration 4 2.2 Company Registration 6 2.3 Registration on Form S-3 7 2.4 Expenses of Registration 7 2.5 Registration Procedures 7 2.6 Indemnification 9 2.7 I |
